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Introduction
Th e anti-infl ammatory, analgesic and antipyretic action 
of non-steroidal anti-infl ammatory drugs (NSAIDs) 
are mediated through inhibition of prostaglandin 
synthesis by inhibiting cyclo-oxygenase (COX) (1). 
COX is the major enzyme in the biosynthesis of pro-
stanoids. Following the discovery in the early 1990s 
of an inducible isoform of COX, it is now known that 
COX exists in at least two isoforms: COX-1 and COX-
2. COX-1 exists in the stomach, intestine, kidneys and 
blood platelets. It synthesizes the prostaglandins that 
(a) regulate the normal physiological processes invol-
ved in protecting the gastrointestinal mucosa and (b) 
maintain the renal function and vascular homeostasis 
(2). Th is role of COX-1 has been referred as a 'house-
keeping' function. In contrast, the inducible isoform 
COX-2, aft er expression induced by several cytokines 
or lipopolysaccharide, produces large amounts of pro-
stanoids that mainly contribute to the pathophysiolo-
gical process of infl ammation. Th e therapeutic eff ects 
of NSAIDs are largely the result of inhibition of the 
enzyme COX-2, whereas the toxic eff ects (disturbing 
platelets, the gut and the kidney) are primarily due to 
the inhibition of COX-1. Th is leads to a lack of throm-
boxane synthesis and impaired platelet aggregation (3).
Diclofenac as non-steroidal anti-infl ammatory drug 
(NSAID) is used in the preoperative and perioperative 
period for alalgesia, for reduction of infl amation and re-
duction of oedema before major orthopaedic procedu-
res. Beside these benifi ts, there are some unwanted side 
eff ects: rash, ringing in the ears, headaches, dizziness, 
drowsiness, abdominal pain, nausea, diarrhea, consti-
pation, hearthburn. NSAIDs reduce ability of blood to 
clot and therfore increase bleeding aft er an injury (4,5). 
NSAIDs are widely used in orthopaedic surgery, and 
diclofenac is a very commonly used NSAID in Ortho-
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paedic Clinic in Clinical Centre of Vojvodina. Th ere 
is concern over the perioperative use of NSAIDs sin-
ce they have the potential to increase perioperative 
blood loss related to their mechanism of action (6). 
We decided to assess the eff ect of diklofenac 
on perioperative blood loss in routine practi-
ce in patients undergoing hip arthroplasty by 
means of a randomized and controlled study.
Methods 
Randomized controlled study was performed in Ort-
hopaedic Clinic, Clinical Centre of Vojvodina in Novi 
Sad, Serbia, during 2008. Investigation included 120 
patients who were to undergo elective total hip repla-
cement for coxarthrosis during spinal (intrathecal) 
and general anaesthesia. Patients were allocated and 
randomized to four equal groups of 30 patients. Gro-
up 1 and 2 which were pretreated with diclofenac and 
operated in general and regional anaesthaesia. Group 3 
and 4 which weren’t pretreated with any analgesic dru-
gs and operated in general and regional anaesthaesia. 
Two groups of patients (who were operated in general 
and regional anaesthesia) were pretreated before surgery 
with diclofenac i.v., on a day before and on a day of sur-
gery. Diclofenac injection were given i.v. three times a 
day. Other two control group (who were operated in ge-
neral and regional anaesthesia) didn’t get any analgesic 
drug. We used 75 mg of diklofenak-sodium (Diklofen˝ 
injection solution 75 mg/3ml Galenika AD, Belgrade).
Th e exclusion factors were: any patients receiving 
NSAIDs, aspirin or anticoagulants before starting 
the trial, and any patients with a history of peptic ul-
cer, renal or liver dysfunction or allergy to any NSAID. 
On the day of surgery patients who were operated in 
general anaesthaesia, were premedicated with Mida-
zolam. General anaesthesia was performed in each 
patient by administering of Propofol, Fentanyl. Rocu-
ronium was used as non-depolarising neuromuscular 
blocker. Sevofl uran and N2O-oxidul as inhalated ana-
esthetics is used during general anaesthesia. Patients 
were intubated and connected to mechanical venti-
lation by volume controlled ventilation. Patients are 
also monitored by standard anaesthesiology parame-
tres: noninvasive blood pressure, heart rate (from the 
electrocardiograph), transcutaneous oxygen saturation, 
respiratory rate, EtCO2 and standard respiratory pa-
rameters. Th ese standard anaesthesiology parameters 
was also observed during fi rst 24 hours of operation. 
Ringer saline solution was given intravenously imme-
diatey before starting surgery. A continous infusion 
of the same solution was administered during sur-
gery and aft er surgery. A colloid solution (Haemaccel) 
was also given to match the volume of blood lost. 
On the day of surgery all patients who were operated 
in regional anaesthaesia, were premedicated with Mi-
dazolam 2 mg. Regional anaesthesia was performed 
in each patient by administering bupivacaine. Ringer 
saline solution was given intravenously immedia-
tey before starting surgery. A continuous infusion of 
the same solution was administeted during surgery 
and aft er surgery. A colloid solution (Haemaccel) 
was also given to match the volume of blood lost. 
Adequate sedation was provided by the patient's request 
during the procedure: the anaesthesiologist administe-
red midazolam 2 mg at a minimum interval of 5 min 
until the patient indicated that the desited level of se-
dation had been reached. Noninvasive blood pressure, 
heart rate (from the electrocardiograph), transcuta-
neous oxygen saturation and respitatory rate were 
continuously monitored during anaesthesia and in the 
intensive care unit during the fi rst 24 h aft er surgery. 
Perioperative blood loss
All operations were performed by the same orthopaedic 
surgeons team. Prophylaxis against thromboembolism 
was started in all patients on the evening before surgery 
with Fraxiparin 0.3 mg s.c. (protocol in our country).
On the day of surgery, fraxiparin 0.3 mg s.c was gi-
ven 24 h aft er the initial dose. Nurses in the opera-
ting room measured perioperative blood loss. To-
tal blood loss was calculated by taking into account 
the amount in the suction bottles, the weight of 
the surgical sponges and the irrigation fl uid used. 
Th e volume of blood collected in the high-vacu-
um wound drainage containers was measured for 
24 h aft er surgery. Th e transfusion trigger for ho-
mologous packed cells was a haemoglobin concen-
tration <8 g/L in the whole postoperative period. 
Statistical analysis 
Th e t-test tested for diff erences between the groups. 
p<0.05 was considered as signifi cant. 
Results 
Patient characteristics data are given in Table I. Th e 
two groups did not diff er for age, height, weight or 
gender. Likewise other variables, e.g. preoperative 
use of β-adrenoceptor receptor blocking drugs, pa-
tients who received sedation during surgery, the use 
of cement and a decline in blood pressure (>25% de-
crease in mean arterial pressure aft er cementation), 
showed no diff erences between groups. Th ere was no 
diff erence in the duration of surgery in either group. 
Perioperative blood loss 
Th e volume of blood loss was signifi cantly higher in 
patients pretreated with diclofenac than with pla-
cebo. Th e volume of blood loss was higher in pati-
ent operated in general anaesthaesia in both grou-
ps, but the blood loss wasn’t statistically signifi cant. 
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Th e volume of perioperative blood loss was 47.1% 
greater in the diclofenac group in general anaethesia 
and 56% greater in patients operated in regional ana-
esthesia compared with the placebo groups (P<0.05). 
Th e measured blood loss in the fi rst 24 h aft er surgery 
also showed a 19.7% higher blood loss in the diclofenac 
group in general anaethesia and 11,4% higher in pati-
ents operated in regional anaesthesia compared with 
the placebo groups. Th is was not statistically diff erent. 
Th e overall blood loss, i.e. the perioperative blood loss 
plus the blood loss in the fi rst 24 h aft er surgery, showed 
an increase of 34.8% in the diclofenac group operated 
in general anaethesia and increase of 32.9% in patients 
operated in regional anaesthesia (P<0.05) (Table 2).
Th e overall blood loss, i.e. the perioperative blood 
loss plus the blood loss in the fi rst 24 h aft er surgery, 
in general anaesthesia compared to regional anae-
sthesia showed an increase of 5,2% in the diclofe-
nac group and increase of 3.6% placebo group. Th is 
was not statistically signifi cant (Figure I). Also me-
asured perioperative blood loss and blood loss du-
ring fi rst 24 h showed not statistically diff erent. 
Th e study had an 86% power to demonstrate a 45% 
diff erence in expected blood loss at a P=0.05 level of 
signifi cance. Th e number of homologous blood tran-
sfusions was nineteen in the diclofenac group and 
sixteen in the placebo group (not signifi cant) during 
the whole period the patients remained in the hospital. 
Discussion
Th e main fi nding is that pretreatment with diclofenac 
before total hip replacement surgery was associated with 
an increase in blood loss both during operation and for 
the fi rst 24 h aft erwards, in regional and in general ana-
esthaesia. Blood loss in regional anaesthaesia compared 
with general anaesthaesia is less but not statisticlly signi-
fi cant. Besides the useful anti-infl ammatory, analgesic 
and antipyretic action of the NSAIDs, the study demon-
strated an undesirable eff ect, namely increased blood loss. 
Researchers from the Case Western Reserve Univer-
sity School of Dental Medicine also recommend the 
discontinuation of NSAIDs prior to surgery to correct 
gum disease because blood loss is two times greater for 
those using the NSAIDs than those not taking it (7).
 Study which compared diclofenac and melocsicam 
also showed that perioperative blood loss patients pre-
treated with diclofenac is signifi cant and patient pre-
treated with meloxicam is less than aft er diclofenac (8).
A. Schmidt et al. concluded that preoperative rectal 
diclofenac off ers no advantage over paracetamol with 
respect to postoperative analgesia in tonsillectomy 
patients but increases intraoperative blood loss (9).
R. Slappendel et al. from St. Maartenskliniek in 
Netherlands in their investigation fi nds that pretre-
Group
Group 1: 
Diclofenac group (in 
general anaesthesia)
Group 2: 
Diclofenac group (in 
regional anaesthesia)
Group 3:
Placebo group (in general 
anaesthesia)
Group 4: 
Placebo group (in 
regional anaesthesia)
Number of patients 30 30 30 30
Gender (m/f) 8/12 9/14 8/11 10/14
Age (yr) 56 59 61 58
Heigh (cm) 174 168 175 170
Weight (kg) 84 82 79 79
Duration of surgery (min) 112 107 123 116
TABLE 1.  Patients characteristic data
FIGURE 1.  Total blood loss in Diclofenac and placebo groups
Group
Group I 
Diclofenac group (in 
general anaesthesia) 
Group II 
Diclofenac group (in 
regional anaesthesia) 
Group III 
Placebo group (in 
general anaesthesia) 
Group IV 
Placebo group (in 
regional anaesthesia) 
Blood loss during surgery (ml) 665 646 452 414
Blood loss 24 h after surgery (ml) 431 412 360 370
Total blood loss (ml) 1096 1042 812 784
TABLE 2.  Blood loss during and after operation
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atment with ibuprofen before elective total hip sur-
gery increases the perioperative blood loss signifi -
cantly and that early discontinuation of non-selective 
non-steroidal anti-infl ammatory drugs is advised (10).
It has been suggested that NSAIDs that selectively in-
hibit COX-2 have fewer side-eff ects (11,12). Th e relati-
onship berween platelet aggregation, thromboxane pro-
duction and serum concentrations of the non-COX-2 
selective drug as diclofenac has been examined (13). A 
single dose of diclofenac-sodium (75 mg) blocked plate-
let aggregation 2h aft er administration (13, 14). Howe-
ver, the eff ect was lost within 24 h. Aft er diclofenac, had 
been given to healthy volunteers, platelet aggregation 
was inhibited for 6, 8 and 11 h, respectively. In the li-
ght of the half-life of diclofenac, these data suggest that 
diclofenac should be stopped 24 h before surgery (15,19). 
Although we tried to reduce as much possible the con-
founding factors in the study (one type of surgery per-
formed one orthopaedic surgeon team), the use of fraxi-
parin for prophylaxis against thromboembolism could 
aff ect the outcome of the study. Diclofenac, but not the 
placebo, increases the prothrombin time (16,18). Other 
weaknesses of the study are the technique of measuring 
blood loss and the relatively high dropout rate. Th e study 
was probably not powerful enough to show whether an 
increase in blood loss resulted in an increased transfusi-
on requirement or perioperative morbidity or mortality. 
Th ese are much more important outcome measures for 
the patient compared with the actual measured blood 
loss. However, they are much more diffi  cult to measure 
and therefore were not primary end-points of the study. 
It is concluded that ceasing NSAIDs suffi  ciently long 
before major orthopaedic surgery reduces perioperative 
blood loss (17). NSAIDs should be replaced before sur-
gery with other analgesics, e.g. paracetamol, or possibly 
COX-2 selective anti-infl ammatory agents, which have a 
better safety profi le concerning peroperative blood loss. 
Th e study had an 86% power to demonstrate a 45% 
diff erence in expected blood loss at a P=0.05 level of 
signifi cance. Th e number of homologous blood tran-
sfusions was nineteen in the diclofenac group and 
sixteen in the placebo group (not signifi cant) during 
the whole period the patients remained in the hospital. 
Conclussion
Pretreatment with diclofenac before major hip 
surgery either general or regional anaesthesia si-
gnifi cantly increases blood loss. Considering the 
presence of relevant adverse eff ects, pretreatment 
with a non-selective NSAID is not recommended. 
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